Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago
Honestly, I wasnt expecting much
The medication doesnt permanently reset your metabolism or appetite regulation
Hypoglycaemia (low blood sugar) may occur, particularly when Mounjaro is used in combination with insulin or sulphonylureas
Gastrointestinal disorders were reported by 62% of the semaglutide group and 42% of the placebo group
These findings contribute to the body of evidence supporting semaglutide in obesity management
